The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.

Riham M KarkeetAbdelrahman N ZekriMohamed M Sayed-AhmedGhada M SherifSalem E SalemAhmed AbdelbaryMariam A FouadSherif Y Saad

Published in: PloS one (2022)

This trial was registered at the Pan African Clinical Trial Registry with identification number PACTR202102664354163 and at ClinicalTrials.gov with identification number NCT04776889.

Keyphrases

clinical trial
phase ii
study protocol
phase iii
prostate cancer
fatty acid
bioinformatics analysis
open label
randomized controlled trial
double blind
benign prostatic hyperplasia